← Back to Search

Deep Brain Stimulation

Adaptive DBS for Parkinson's Disease (ADAPT-PD Trial)

N/A
Waitlist Available
Led By Helen Bronte-Stewart, MD, MSE
Research Sponsored by MedtronicNeuro
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is implanted with specific Medtronic DBS leads and extensions bilaterally in the same target (physician confirmed), STN or GPi
Subject has idiopathic Parkinson's disease
Must not have
Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
Subject is under the age of 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 1.5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will show if aDBS is safe and effective for treating Parkinson's disease.

Who is the study for?
This trial is for adults with stable Parkinson's disease who respond to DBS therapy, can attend all study visits, and are not pregnant. They must use specific Medtronic DBS leads and have detectable Beta band amplitude in their brain signals. Excluded are those under 18, breastfeeding women, individuals with multiple brain implants or enrolled in other studies that could affect results.
What is being tested?
The study tests the safety and effectiveness of adaptive Deep Brain Stimulation (aDBS) for Parkinson's patients. It involves using aDBS technology tailored to individual patient responses compared to standard settings while monitoring its impact on Parkinson's symptoms.
What are the potential side effects?
While not explicitly listed here, potential side effects may include discomfort at the stimulation site, headache, dizziness, involuntary movements or worsening of Parkinson’s symptoms due to stimulation adjustments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have Medtronic DBS leads in my brain for Parkinson's or dystonia.
Select...
I have been diagnosed with Parkinson's disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I need treatments like diathermy, TMS, or ECT for my condition.
Select...
I am under 18 years old.
Select...
I cannot use or tolerate wearable devices.
Select...
I have or plan to get a pump implanted for Parkinson's treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 1.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, approximately 1.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
On time without troublesome dyskinesia
Secondary study objectives
Stimulation energy use
Other study objectives
Safety (SAEs, AEs and DDs)
Safety (Stimulation-related AEs)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: aDBS Single ThresholdExperimental Treatment1 Intervention
Adaptive DBS Single Threshold Mode
Group II: aDBS Dual ThresholdExperimental Treatment1 Intervention
Adaptive DBS Dual Threshold Mode

Find a Location

Who is running the clinical trial?

MedtronicNeuroLead Sponsor
71 Previous Clinical Trials
21,050 Total Patients Enrolled
Helen Bronte-Stewart, MD, MSEPrincipal InvestigatorStanford University

Media Library

Adaptive DBS (Deep Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04547712 — N/A
Parkinson's Disease Research Study Groups: aDBS Single Threshold, aDBS Dual Threshold
Parkinson's Disease Clinical Trial 2023: Adaptive DBS Highlights & Side Effects. Trial Name: NCT04547712 — N/A
Adaptive DBS (Deep Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04547712 — N/A
~17 spots leftby Nov 2025